Barclays Maintains an 'Overweight' on Celgene (CELG); Stumble in Europe, But Expect Continued U.S. Growth

Barclays maintains an 'Overweight' on Celgene (NASDAQ: CELG) price target of $74.00 (from $83.00).

Analyst, Ying Huang, said, "Withdrawal of European application is disappointing, yet not completely unexpected...We lower our PT to $74, but stock should be supported by floor valuation of $60. Even without front-line maintenance approval in Europe, Revlimid should continue to grow in both the US and Europe on longer duration and higher number of patients."

Barclays lowers FY13 EPS estimate from $5.27 to $4.86.

For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.

Shares of Celgene closed at $59.45 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• GMR Airports Infrastructure (GMRI:IN) PT Raised to INR99 at ICICI Securities
• Freedom Broker Upgrades Lifeway Foods (LWAY) to Buy